Dec 28, 2022 02:18PM
Dec 28, 2022 07:30AM
Nov 10, 2022 07:30AM
Oct 26, 2022 07:30AM
Sep 11, 2022 09:00PM
Sep 6, 2022 09:26PM
Aug 31, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Molecular Partners, TG Therapeutics, 17EdTech, and Enochian and Encourages Investors to Contact the Fir
Aug 26, 2022 09:00PM
Aug 25, 2022 07:31AM
Aug 25, 2022 07:30AM
Aug 21, 2022 09:00PM
Aug 15, 2022 09:00PM
Aug 10, 2022 09:00PM
Aug 8, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Aug 5, 2022 09:00PM
Jul 31, 2022 09:00PM
Jul 25, 2022 09:00PM
Jul 20, 2022 09:00PM
Jun 27, 2022 07:31AM
Jun 27, 2022 07:30AM
May 31, 2022 07:30AM TG Therapeutics (TGTX) Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 31, 2022 07:30AM
Apr 19, 2022 08:36AM
Apr 15, 2022 08:31AM
Apr 15, 2022 08:30AM
Apr 6, 2022 07:30AM
Mar 10, 2022 08:16AM
Mar 10, 2022 08:15AM TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
Mar 3, 2022 08:00AM
Mar 3, 2022 08:00AM
Mar 1, 2022 07:31AM
Mar 1, 2022 07:30AM
Feb 25, 2022 07:33AM
Feb 25, 2022 07:30AM
Dec 14, 2021 07:15AM TG Therapeutics (TGTX) Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of MS
Dec 14, 2021 07:15AM
Nov 30, 2021 07:33AM
Nov 30, 2021 07:30AM
Nov 4, 2021 07:00AM
Sep 23, 2021 08:00AM
Sep 20, 2021 07:36AM
Sep 20, 2021 07:30AM TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Aug 30, 2021 07:30AM
Aug 2, 2021 07:00AM
Jun 29, 2021 07:30AM
May 25, 2021 07:03AM
May 25, 2021 07:00AM
Dec 7, 2020 10:15AM
Dec 1, 2020 07:02AM TG Therapeutics (TGTX) Initiates Rolling Submission of BLA to FDA for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
Dec 1, 2020 07:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All